Multivessel vs. culprit-vessel only percutaneous coronary interventions in acute myocardial infarction and cardiogenic shock: a systematic review and meta-analysis of prospective randomized and retrospective studies.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Gill, Gauravpal S.
  • Thandra, Abhishek
  • Kanmanthareddy, Arun
  • Alla, Venkata Mahesh
  • Garcia-Garcia, Hector M.

Grupos

Abstract

Aims Studies comparing outcomes of multivessel (MV) vs. culprit-vessel (CV) only percutaneous coronary intervention (PCI) during index cardiac catheterization in patients presenting with acute myocardial infarction (MI) and cardiogenic shock (CS) have reported conflicting results. In this systematic review we aim to investigate outcomes with MV vs. CV-only revascularization strategies in patients with acute MI and CS. Methods and results PubMed, Google Scholar, CINAHL and Cochrane databases were queried for studies comparing MV vs. CV PCI in patients with acute MI and CS. Data were extracted and pooled by means of random effects model. Primary outcome was early all-cause mortality (up to 30 days), while the secondary outcomes included late all-cause mortality (mean, 11.4 months), stroke, new renal replacement therapy, reinfarction, repeat revascularization, and bleeding. Pooled odds ratio (OR), 95% confidence intervals (CIs), and number needed to harm (NNH) were calculated. A total of 16 studies enrolling 75 431 patients were included. The MV PCI was associated with higher risk of early mortality [OR 1.17, 95% CI (1.00-1.35); P = 0.04; NNH = 62], stroke [1.15 (1.03-1.29); P = 0.01; NNH = 351], and new renal replacement therapy [1.33 (1.06-1.67); P = 0.01; NNH = 61]; and with lower risk of repeat revascularization [0.61 (0.41-0.89); P = 0.01] when compared with CV PCI. No significant difference was observed in late-term mortality [1.02 (0.84-1.25); P = 0.84], risk of reinfarction [1.13 (0.94-1.35); P = 0.18], or bleeding [1.21 (0.94-1.55); P = 0.13] between groups. Conclusion Among patients with acute MI and CS, MV PCI during index cardiac catheterization was associated with higher risk of early mortality, stroke, and renal replacement therapy.

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Datos de la publicación

ISSN/ISSNe:
2048-8726, 2048-8734

EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE  SAGE Publications Ltd

Tipo:
Article
Páginas:
558-569
Factor de Impacto:
1,467 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Myocardial infarction; Acute coronary syndrome; Cardiogenic shock; Culprit vessel; Multivessel; Percutaneous coronary intervention

Campos de estudio

Proyectos asociados

MECANISMOS DE ENFERMEDAD EN LA MIOCARDIOPATIA ARRITMOGENICA, MEJORAS EN SU DIAGNOSTICO Y BUSQUEDA DE DIANAS TERAPEUTICAS.

Investigador Principal: ESTHER ZORIO GRIMA

PI14/01477 . INSTITUTO DE SALUD CARLOS III . 2015

INCORPORACIÓN GRUPOS CIBER. DR. DOLZ

Investigador Principal: LUIS VICENTE MARTÍNEZ DOLZ

CB16/11/00261 . INSTITUTO DE SALUD CARLOS III . 2017

ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, BASADO EN EVENTOS, QUE COMPARA LA EFICACIA Y SEGURIDAD DE RIVAROXABAN CON PLACEBO EN LA REDUCCIÓN DEL RIESGO DE MUERTE, INFARTO DE MIOCARDIO O ICTUS, EN PACIENTES CON INSUFICIENCIA CARDIACA Y ENFERMEDAD ARTERIAL CORONARIA SIGNIFICATIVA TRAS UN EPISODIO DE INSUFICIENCIA CARDIACA DESCOMPENSADA.

Investigador Principal: LUIS ALMENAR BONET

RIVAROXHFA3001/BAY59-7939/16302 . 2013

EVALUACIÓN, EN PACIENTES CON PROCESOS MÉDICOS, DE RIVAROXABAN FRENTE A PLACEBO EN LA REDUCCIÓN DEL RIESGO DE TROMBOEMBOLISMO VENOSO DESPUÉS DEL ALTA HOSPITALARIA. (MARINER).

Investigador Principal: JOSÉ ANTONIO TODOLÍ PARRA

RIVAROXDVT3002/BAY59-7939/17261

Ensayo clínico aleatorizado para evaluar el efecto de los betabloqueantes y los antiagregantes plaquetarios en pacientes con disección espontánea de la arteria coronaria.

Investigador Principal: JOSÉ LUIS DÍEZ GIL

BA-SCAD . 2021

ASSESSING THE EFFECT OF DAPAGLIFOZIN ON PLAQUE PROGRESSION IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION DAPA-PLACA.

Investigador Principal: JORGE SANZ SÁNCHEZ

DAPA-PLACA . 2021

Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures. DOAC-NOSTOP.

Investigador Principal: JORGE SANZ SÁNCHEZ

DOAC-NOSTOP . 2021

Cita

Compartir